Working... Menu
Trial record 36 of 141 for:    MPL

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00697931
Recruitment Status : Completed
First Posted : June 16, 2008
Last Update Posted : June 16, 2008
Information provided by:

Brief Summary:
The purpose of this study is to compare the immunogenicity and reactogenicity of the adjuvanted recombinant hepatitis B vaccine with that of Engerix™-B when both are injected according to a three dose schedule (0, 1, 6 months) in an adult non-responder population

Condition or disease Intervention/treatment Phase
Hepatitis B Biological: Recombinant MPL- adjuvanted hepatitis B vaccine Biological: Engerix™-B Phase 3

Detailed Description:
At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 116 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Study to Compare the Immunogenicity and Reactogenicity of GSK Biologicals; (Previously SmithKline Beecham Biologicals') MPL-Adjuvanted Recombinant Hepatitis B Vaccine With That of Engerix™-B in an Adult Non-Responder Population
Study Start Date : May 1997
Actual Primary Completion Date : June 1998
Actual Study Completion Date : June 1998

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Group A Biological: Recombinant MPL- adjuvanted hepatitis B vaccine
Intramuscular injection, 3 doses

Active Comparator: Group B Biological: Engerix™-B
Intramuscular injection, 3 doses

Primary Outcome Measures :
  1. Anti-HBs antibody concentrations [ Time Frame: At month 7 ]

Secondary Outcome Measures :
  1. Anti-HBs antibody concentrations [ Time Frame: At months 2, 6, 7 and 12 ]
  2. Occurrence and intensity of solicited local symptoms [ Time Frame: 4-day follow-up after vaccination ]
  3. Occurrence, intensity and relationship of solicited general symptoms [ Time Frame: 4-day follow-up after vaccination ]
  4. Occurrence, intensity and relationship to vaccination of unsolicited symptoms [ Time Frame: Within 30 days after vaccination ]
  5. Incidence of serious AEs [ Time Frame: Throughout the entire study up to and including 30 days after the last vaccination ]
  6. Cell mediated immunity [ Time Frame: At months 0, 2, 6, 7, 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age: older than 18 years of age.
  • Documented non-responders 2 to 5 months after having received 4 doses of a hepatitis B vaccine
  • Good physical condition as established by clinical examination and history taking at the time of entry.
  • Female participants who are at risk to become pregnant will be on a contraceptive programme if necessary during the study period.
  • Written informed consent obtained from the subjects

Exclusion Criteria:

  • Positive at screening for anti-HBV antibodies
  • Elevated serum liver enzymes.
  • History of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease.
  • Any acute disease at the moment of entry.
  • Chronic alcohol consumption.
  • Hepatomegaly, right upper quadrant abdominal pain or tenderness.
  • Any chronic drug treatment, including any treatment with immunosuppressive drugs, which in the investigator's opinion, precludes inclusion into the study.
  • History of allergic disease likely to be stimulated by any component of the vaccine.
  • Simultaneous participation in any other clinical trial.
  • Previous vaccination with an MPL containing vaccine.
  • Administration of immunoglobulins 6 months before and during the whole study period
  • Vaccination one month before and one month after each dose of the study vaccine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00697931

Layout table for location information
GSK Clinical Trials Call Center
Leuven, Belgium
Sponsors and Collaborators
Layout table for investigator information
Study Director: Clinical Trials GlaxoSmithKline

Layout table for additonal information
Responsible Party: Isabelle Harpigny, GSK Identifier: NCT00697931     History of Changes
Other Study ID Numbers: 208129/021
First Posted: June 16, 2008    Key Record Dates
Last Update Posted: June 16, 2008
Last Verified: June 2008

Keywords provided by GlaxoSmithKline:
Hepatitis B
Recombinant Hepatitis B vaccine

Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis B
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Immunologic Factors
Physiological Effects of Drugs